盛視科技(002990.SZ):收到發明專利權通知書
格隆匯9月5日丨盛視科技(002990.SZ)公佈,公司及全資子公司深圳市盛視技術有限公司分別於近日收到國家知識產權局下發的《授予發明專利權通知書》,分別為側向切膠機構及施封貼標機,一種應急設備管理系統。
上述發明專利為公司自主研發取得,是公司持續創新的成果,上述發明專利的單獨使用以及與其他平台的組合使用將對公司鞏固在相關領域的優勢具有積極影響,同時有利於公司進一步完善知識產權保護體系,充分發揮自主知識產權優勢,促進技術創新,提升公司核心競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.